At the 2025 Annual Meeting of the Optometric Vision Development & Rehabilitation Association (OVDRA)—the premier U.S. organization for neuro-optometric rehabilitation—ALTIUS® presented new clinical data on photophobia management. Rachel C. Ayars, ABO, NCLE (Director, ALTIUS®), Dr. Charles Shidlofsky, OD, FOVDR, FNAP, and Janice Nilsson, COMT, OSC, engaged directly with attending doctors during the poster presentation.
The data demonstrated a statistically significant reduction in light sensitivity symptoms—average patient scores dropped from 8.86 to 2.58 after one month of ALTIUS® use. The event validated ALTIUS® as a disruptive, clinically relevant innovation for patients with migraine, concussion, and light-triggered neurological conditions. It also created meaningful opportunities to connect with leading neuro-optometric physicians and reinforce ALTIUS®’ growing role in the medical management of photosensitivity.
